Brazilian study on Ivermectin shows effectiveness against COVID-19

I chopped up the quote from the study to make it easier to read. Everything below except for the conclusion was in a single paragraph. They found Ivermectin reduced mortality by 70% and reduced hospitalization by 67%.

Of the 223,128 citizens of Itajaí considered for the study, a total of 159,561 subjects were included in the analysis: 

113,845 (71.3%) regular ivermectin users and 45,716 (23.3%) non-users. 

Of these, 4,311 ivermectin users were infected, among which 4,197 were from the city of Itajaí (3.7% infection rate), and 3,034 non-users (from Itajaí) were infected (6.6% infection rate),

with a 44% reduction in COVID-19 infection rate (risk ratio [RR], 0.56; 95% confidence interval (95% CI), 0.53-0.58; p < 0.0001). 

Using PSM, two cohorts of 3,034 subjects suffering from COVID-19 infection were compared.

The regular use of ivermectin led to a 68% reduction in COVID-19 mortality (25 [0.8%] versus 79 [2.6%] among ivermectin non-users; RR, 0.32; 95% CI, 0.20-0.49; p < 0.0001).

When adjusted for residual variables, reduction in mortality rate was 70% (RR, 0.30; 95% CI, 0.19-0.46; p < 0.0001).

There was a 56% reduction in hospitalization rate (44 versus 99 hospitalizations among ivermectin users and non-users, respectively; RR, 0.44; 95% CI, 0.31-0.63; p < 0.0001).

After adjustment for residual variables, reduction in hospitalization rate was 67% (RR, 0.33; 95% CI, 023-0.66; p < 0.0001).

Conclusion: In this large PSM study, regular use of ivermectin as a prophylactic agent was associated with significantly reduced COVID-19 infection, hospitalization, and mortality rates.